NCT00021034View on ClinicalTrials.gov

Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

March 31, 2001

Primary Completion Date

August 31, 2001

Study Completion Date

August 31, 2001

Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG

chemotherapy

DRUG

taurolidine

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00021034 - Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter